Compounds and methods for the treatment of urogenital disorders

• US 6,987,129 B2
• Filed: 03/06/2002
• Issued: 01/17/2006
• Est. Priority Date: 03/06/2001
• Status: Expired due to Fees

• Current Assignee: Cellegy Pharmaceuticals, Inc.
• Original Assignee: Cellegy Pharmaceuticals, Inc.
• Inventors: Grayson, Stephen, Mak, Vivien H. W.
• Primary Examiner(s): Wang, Shengjun
• Application Number:
  US10/094,409
• Publication Number:
  US 20020198136A1
• Time in Patent Office: 1,413 Days
• Field of Search: 514/509, 514/564, 514/634, 514/228.8
• US Class Current: 514/509
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 38/446 Superoxide dismutase (1.15)
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates and cGMP-dependent protein kinase activators (e.g., cGMP mimetics).

Claims

1. A method for relieving the vulvar pain of vulvodynia in a patient, the method comprising topically administering to the affected vulvar area of the patient a NO donor in a therapeutically effective amount, wherein the vulvar pain which is not caused by dyspaerunia is relieved.

2. The method of claim 1, wherein the NO donor is nitroglycerin.

3. The method of claim 1, wherein said NO donor is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.

4. The method of claim 1, wherein said NO donor is delivered continuously.

5. The method of claim 1, wherein the NO donor is formulated in a unit dosage.

6. The method of claim 1, wherein the patient is treated to prevent a relapse of vulvodynia.

7. The method of claim 1, wherein the patient is human.

8. The method of claim 1, wherein the vulvar pain of vulvodynia is constant.

9. The method of claim 1, wherein the vulvar pain of vulvodynia is intermittent.

10. The method of claim 1, wherein the vulvar pain of vulvodynia is diffuse.

11. The method of claim 1, wherein the vulvar pain of vulvodynia is localized.

12. The method of claim 1, wherein the NO donor is delivered locally by topical application in a sustained release format.

13. The method of claim 1, wherein the method consists essentially of administering the NO donor.

14. The method of claim 12, wherein the NO donor is nitroglycerin.